Introduction
The concept of metabolic syndrome (MS) refers to a cluster of metabolic risk factors, such as glucose intolerance, dyslipidemia, central obesity, and hypertension, which are major risk factors for cardiovascular and cerebrovascular diseases [1] . Recent reports have shown that MS represents a major economic burden and public health problem [2, 3] . Epilepsy has been reported to be associated with a higher risk of cardiovascular diseases [4, 5] . In people with epilepsy, a sedentary lifestyle and antiepileptic drugs (AEDs) can contribute to obesity and MS [6, 7] . Numerous studies have explored the effects of different AEDs on specific metabolic and anthropometric parameters, such as the plasma lipid concentration and occurrence of obesity. However, only a few studies, with conflicting results, have examined the presence of MS in patients with epilepsy. Some previous studies focused only on specific populations (females, children). Others studied different metabolic side effects of AEDs, such that the occurrence of MS was assessed only indirectly [8] [9] [10] [11] [12] [13] . Verrotti et al. [8] showed that the presence of MS in children and adolescents treated with valproate (VPA) who became obese did not differ from the MS prevalence in otherwise healthy overweight subjects. Pylvä nen et al. also reported that the frequency of MS was similar between VPA-treated adults and control subjects [9] . A study evaluating the prevalence of MS among Chinese adult obese patients with epilepsy treated with VPA showed a tendency toward a higher risk of MS compared to obese control subjects, although this difference was not statistically significant [10] . On the other hand, Kim and Lee reported that females with epilepsy on VPA monotherapy more frequently have MS compared to females treated with carbamazepine (CBZ), lamotrigine (LTG), or topiramate (TPM) [11] . Furthermore, nonalcoholic fatty liver disease, which is the hepatic manifestation of MS, occurred more frequently in patients on VPA treatment compared to patients on CBZ or LTG monotherapy [12] .
Recently, we conducted a study comparing MS risk in VPAtreated patients and in the general population in Estonia. We found no difference in MS risk between these two groups [14] . CBZ and VPA are among the most widely used AEDs in Estonia and worldwide [15] . In people with epilepsy who are indicated for AED treatment, physicians frequently choose between these two drugs. Information on the potential relationship between CBZ or VPA and MS risk could help physicians in this decision-making process. In our opinion, current knowledge about this topic is insufficient and inconsistent. Therefore, the aim of this cross-sectional populationbased study was to compare MS risk among adult people with epilepsy who were treated with VPA or CBZ. The secondary aim was to evaluate possible relevant factors for MS development, such as age, sex, epilepsy etiology, seizure frequency, doses of AEDs, and concomitant diseases.
Materials and methods

Subjects
Using the prescription database of the Estonian Health Insurance Fund, we identified patients with epilepsy from six southern Estonian counties (including the city of Tartu and Tartu County) who were prescribed VPA and patients with epilepsy from the city of Tartu and Tartu County who were prescribed CBZ. Inhabitants of southern Estonia have similar distributions of socioeconomic status and ethnicity. Exclusion criteria for patients with epilepsy treated with CBZ were the same as for patients treated with VPA and are described in our previous report as follows: age 18 years, duration of VPA or CBZ monotherapy < 3 months, polytherapy with other AEDs, and pregnancy [14] . As physical inactivity is a major risk factor of MS, and as the aim of the study was to evaluate possible relationships between AEDs, epilepsy syndromes, and MS risk, patients with severe physical or mental disabilities related to severe brain damage were not included. Specifically, patients who lived at nursing homes or who were dependent at or outside the home were excluded. Study participants should be able to engage in normal occupational and social activities, despite minor physical or mental deficits. Patients with disturbances of the endocrine system, such as diabetes or thyroid dysfunction, were not excluded.
On the day of the study, subjects who met the inclusion criteria were invited to the outpatient clinic of the Department of Neurology at Tartu University Hospital. The first author interviewed and clinically examined all patients. Medical histories of participants were documented during the evaluation meeting. Concomitant diseases of relevance to the study, including known endocrinopathies, lipid metabolism disorders, and vascular diseases, were noted. Blood pressure, waist circumference, weight, and height were measured. Body mass index (BMI) was calculated as the weight (in kg) divided by height squared (in m 2 ). Blood samples were obtained in the morning (between 08:00 and 11:00) after an overnight fast (!10 h) for the analysis of serum insulin, Cpeptide, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and fasting blood glucose (FBG) concentrations. Patients with unmeasurable serum VPA or CBZ levels were excluded because of poor compliance. During the face-to-face interviews and the review of previous medical history, the patients' epilepsy diagnoses were re-evaluated, and the date of the last seizure was recorded. Epileptic syndromes were classified based on the recently proposed International League against Epilepsy classification [16] . The date of initiation, duration, and current dosage of VPA or CBZ treatment were recorded. Patients were asked whether they had noticed any change in body weight after initiation of VPA or CBZ treatment. The final regression analysis included concomitant conditions as a covariate. Concomitant conditions included psychiatric comorbidities treated with antidepressants and/or antipsychotics, and thyroid dysfunction. The regular use of medications for the treatment of arterial hypertension, dyslipidemia, or previously diagnosed diabetes was not considered as an independent covariate in the regression analysis, because the use of these medications is included in the definition of MS. The Ethics Review Committee on Human Research of Tartu University approved the study. All participants provided written informed consent.
Assays
FBG levels were measured by the hexokinase method. HDL-C and TG concentrations were measured by an enzymatic colorimetric assay. Plasma insulin and C-peptide concentrations were measured by an electrochemiluminescent assay (COBAS 6000 Analyzer; Roche). VPA and CBZ concentrations were measured by fluorescence polarization assay (COBAS INTEGRA 800 Plus Analyzer; Roche, Basel, Switzerland). 
Definition of MS
Statistical analysis
Descriptive analytical methods, such as the calculation of means, standard deviations, medians, and interquartile ranges (IQRs), were used for continuous variables, depending on the distribution. Linear regression models were used to compare anthropometric and laboratory data between VPA-and CBZ-treated patients. Multiple logistic regression analysis was performed to identify factors associated with MS development in VPA-and CBZ-treated patients. The final multiple logistic regression model was adjusted for age, sex, epilepsy etiology, seizure occurrence in the last year, treatment duration, and concomitant diseases. Odds ratios (ORs) and 95% confidence intervals (95% CIs) are reported. The R software package (The R Foundation for Statistical Computing; version 2.15.1) was used for statistical analyses. The significance level was set at P < 0.05.
Results
A total of 384 (206 men, 178 women) and 484 (292 men, 192 women) patients with epilepsy diagnoses who had received VPA or CBZ treatment, respectively, were initially identified. Applying the data collection methods described above, 118 VPAtreated patients (63 men, 55 women) and 95 CBZ-treated patients (55 men, 40 women) were included in the final study sample. From the initial drug prescription database, 17 (4.4%) VPA-treated subjects and 138 (28.5%) CBZ-treated patients were not included in the final sample due to severe physical or mental disability related to brain damage caused by severe head injury, cerebrovascular disease, progressive brain neoplasm, pre-or perinatal risk factors, central nervous system infection, or other factors (Fig. 1) .
In the final sample, most of the VPA-treated patients had a genetic epilepsy etiology (P < 0.0001), whereas CBZ-treated patients more frequently had a structural or metabolic cause of epilepsy (P < 0.0001). Median ages of patients treated with VPA and CBZ were 32 years (IQR, 24-45 years) and 56 years (IQR, 43-66 years), respectively. Clinical characteristics of the patients are summarized in Table 1 . Twenty-five patients had psychiatric comorbidities that were treated with antidepressants and/or antipsychotics. Five patients had been diagnosed previously with thyroid dysfunction. Nine patients had been previously diagnosed with diabetes.
The crude prevalence of MS in VPA-treated patients was 20.3% (95% CI, 13.7-28.9%) and in CBZ-treated patients was 40.0% (95% CI, 30.0-50.0%). Stepwise logistic regression analysis revealed no significant correlation between MS development in patients with epilepsy and clinical characteristics, such as sex, epilepsy etiology, treatment with VPA or CBZ, seizure occurrence in the last year, HOMA-IR, and concomitant diseases. The only factor to be significantly correlated with the occurrence of MS in people with epilepsy was the patient's age, which showed a positive correlation (OR = 1.03; 95% CI, 1.01-1.06; P = 0.007). There was no correlation between the daily dosage of medication and the risk of MS in patients on CBZ treatment (P = 0.948). In VPA-treated patients, we observed a tendency toward a positive correlation between drug dose and risk of MS, which did not Regarding individual components of MS, a lower proportion of CBZ-treated patients had abnormally low HDL-C levels (OR = 0.10; 95% CI, 0.02-0.42; P = 0.002). This effect was more pronounced in women (OR = 0.02; 95% CI, 0.001-0.22; P = 0.002) compared to men (OR = 0.47; 95% CI, 0.07-2.99; P = 0.425). A higher proportion of VPA-treated females had waist circumference values exceeding 88 cm (OR = 5.51; 95% CI, 1.05-29.01; P = 0.044). A lower proportion of VPA-treated patients had abnormally high FBG concentrations (OR = 0.30; 95% CI, 0.13-0.69; P = 0.004, Table 2 ). Overall, patients on VPA treatment had lower concentrations of HDL-C (P < 0.0001) and tended to have lower concentrations of FBG (P = 0.055, Table 3 ). Arterial hypertension (83.3%), abdominal obesity (83.3%), and increased TG level (75.0%) were the most common abnormalities in VPA-treated patients with MS. In CBZtreated patients, the most common MS components were arterial hypertension (92.1%), increased FBG concentration (84.2%), and abdominal obesity (78.9%).
Discussion
The primary aim of this study was to determine whether treatment with either of the two most frequently used AEDs is correlated with the risk of MS and its components in patients with epilepsy. We identified all patients from selected southern Estonia counties who were prescribed with VPA or CBZ. The final sample included 213 persons with epilepsy treated with VPA or CBZ monotherapy. The risk of MS appeared to be similar in both groups. However, due to the limitations of the cross-sectional study design, we did not have data on body weight or MS prevalence before the start of AED treatment. Moreover, many patients had been diagnosed with epilepsy for decades, and we were unable to collect data from all patients concerning their previously used AEDs and AED dosages, because old medical documentation was missing. Therefore, whether treatment with VPA or CBZ directly influences the risk of MS could not be ascertained. Females on VPA treatment had a higher risk of MS compared to males, although this difference was not statistically significant. Similarly, Kim and Lee reported that women with epilepsy on VPA monotherapy more frequently suffer from MS compared to women treated with CBZ, LTG, or TPM [11] . In our study, two MS components (increased waist circumference and decreased HDL-C concentration) were more frequently observed in VPA-treated females compared to males. From a practical perspective, these results suggest that treatment with VPA or CBZ in males probably is not correlated with different MS risk in the future. However, in females with a higher risk of cardiovascular diseases, AEDs other than VPA could be considered first.
In the initial study population, a significantly higher number of CBZ-compared to VPA-treated patients had severe physical or mental disability due to brain damage and were excluded from the final sample. This difference between patients treated with different AEDs can be explained by the fact that CBZ is the first-line AED for focal seizures, which are frequently caused by focal brain damage of different etiologies [18] . Although the etiology of epilepsy differed between the treatment groups, we did not find a significant correlation between the risk of MS and epilepsy etiology.
A very consistent finding across different populations is that the prevalence of MS is highly age-dependent [19] . For example, in an Estonian population, the prevalence of MS was determined to be 19% in the 20-to 44-year-old age group compared to 45% in the 61-to 74-year-old age group [20] . In our sample, age was the only significant risk factor for MS in patients with epilepsy. This result is probably a reflection of the global trend. Our study showed that the presence of MS was associated with higher VPA doses, with borderline statistical significance (P = 0.075), and was not associated with CBZ doses. Consistent with our result, Fang et al. reported a similar association between higher VPA doses and MS (P = 0.049) [10] . Another study in children reported a significant correlation between the daily administered VPA dose and insulin resistance, which is one of the main signs of MS [21] . Therefore, to minimize the possibility of occurrence of MS in VPA-treated patients, the lowest effective dose should be advised.
It is widely accepted that VPA treatment can cause an increase in body weight [22] . Although the real magnitude of this problem is unknown, the reported frequency of weight gain in studies varies between 10% and 70% [23] . Although less often, weight gain also has been associated with CBZ treatment [24] [25] [26] . We found no difference in BMI between VPA-and CBZ-treated subjects, which could be explained by the similar effect of both drugs on weight and by the prevalence design of our study. Patients whose VPA or CBZ treatment was discontinued due to side effects were not included in our cohort. Nevertheless, the results likely reflect the true clinical management of AED-related side effects in our population. The real pathogenic mechanism underlying VPA-induced weight gain is unknown, although many authors believe that IR may play a central role. It is not clear, however, whether this IR is a result of weight gain, or whether VPA treatment itself can directly cause hyperinsulinemia and IR [22] . Increasing evidence suggests that VPA treatment is associated with lower FBG concentration, a finding that is not consistent with the reduced insulin sensitivity hypothesis [14, [27] [28] [29] [30] . In our study, patients on VPA treatment had lower FBG concentrations (with borderline significance), and their insulin concentrations were not increased. These findings argue against the presence of increased IR among these patients. One possible mechanism to explain the weight gain in VPA-treated patients could be that the VPA-mediated decrease in glucose levels stimulates the appetite, leading to obesity and, probably, increased IR [31, 32] .
Patients treated with CBZ had significantly higher HDL-C concentrations. This effect was especially pronounced in women. TG levels also tended to be higher in this patient group, although without reaching the level of statistical significance. The lipidincreasing effect of CBZ has been described in the medical literature, as recently reviewed by Katsiki et al. [33] and Vyas et al. [34] . CBZ is a well-known enhancer of the hepatic cytochrome P450 enzyme system, which is extensively involved in the synthesis and metabolism of cholesterol. In contrast, VPA is an enzyme inhibitor and exerts the opposite action from CBZ [35] . CBZ monotherapy has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, HDL-C, and TG concentrations [33, 36] . Interestingly, the observed gender effect of CBZ on HDL-C was also reported by others [37] .
Although the enzyme-inducing effect of CBZ undoubtedly causes dyslipidemia in patients treated with this drug, the increased concentrations of some lipid fractions, especially HDL-C, could potentially have a protective effect against MS. Indeed, in our study, the presence of a pathologically low plasma HDL-C concentration was significantly less frequent in CBZ-treated patients. This trend probably decreased the overall prevalence of MS in this group. However, in populations of patients who use lipid metabolism-modifying drugs, such as CBZ, the MS diagnostic criteria should be applied with caution, considering the direct effects of such drugs on these criteria.
The strengths of our study include the population-based design and the cohort size, which is larger than in other published studies investigating MS risk in patients with epilepsy. On the other hand, the heterogeneity of patients treated either with VPA or CBZ was a significant confounding factor. One of the most important determinants of MS, patient age, differed between the two cohorts. VPAtreated patients were younger than CBZ-treated patients, as VPA is used mainly for the treatment of generalized epilepsies, which usually manifest in children and young adults. For the same reason, the epilepsy etiology was different between the two groups, which could have an effect on MS risk. Moreover, our study may have underestimated the effect of epileptic syndrome on the MS risk. It was difficult to differentiate the potential effect of VPA from the effect of generalized epilepsy on MS risk, as almost no patients with generalized epilepsy were treated with CBZ. Physical activity level and diet, as important MS risk factors, were not assessed in the current study, constituting another important limitation. Lack of information on patient weight and MS status before treatment, as well as partially missing data on previously used AEDs, prevents us from making conclusions about the cause-and-effect relationships of the studied AEDs and MS. Finally, a substantial proportion of patients from the initial drug prescription database refused to participate or had incorrect or missing contact information.
In conclusion, although the general risk of MS seemed to be similar in these patient cohorts, the distribution of MS components was different. Patients on CBZ or VPA treatment less frequently had decreased HDL-C or increased FBG concentrations, respectively. To minimize the possibility of occurrence of MS in VPA-treated patients, the lowest effective dose should be advised. Finally, females on VPA treatment could be at a higher risk of MS than males.
